Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene's BLA for Neuroblastoma Therapy Accepted for Review in China

publication date: Nov 10, 2020

Beijing's BeiGene reported that China regulators will review its BLA for a novel neuroblastoma therapy. Qarbiza^® (dinutuximab beta) is a targeted immunotherapy approved in the EU to treat high-risk neuroblastoma in patients aged 12 months and above. High-risk neuroblastoma, an aggressive neoplasm, is the most common childhood solid tumor that originates outside of the brain. BeiGene in-licensed China rights to dinutuximab beta from EUSA, a company that operates in the US and EU. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.